Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol
- PMID: 23250049
- DOI: 10.1136/gutjnl-2012-304038
Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol
Abstract
Objective: Non-selective β-blockers or endoscopic band ligation (EBL) are recommended for primary prophylaxis of variceal bleeding in patients with oesophageal varices. Additional α-adrenergic blockade (as by carvedilol) may increase the number of patients with haemodynamic response (reduction in hepatic venous pressure gradient (HVPG) of ≥ 20% or to values <12 mm Hg).
Design: Patients with oesophageal varices undergoing measurement of HVPG before and under propranolol treatment (80-160 mg/day) were included. HVPG responders were kept on propranolol (PROP group), while non-responders were placed on carvedilol (6.25-50 mg/day). Carvedilol responders continued treatment (CARV group), while non-responders to carvedilol underwent EBL. The primary aim was to assess haemodynamic response rates to carvedilol in propranolol non-responders.
Results: 36% (37/104) of patients showed a HVPG response to propranolol. Among the propranolol non-responders 56% (38/67) eventually achieved a haemodynamic response with carvedilol, while 44% (29/67) patients were finally treated with EBL. The decrease in HVPG was significantly greater with carvedilol (median 12.5 mg/day) than with propranolol (median 100 mg/day): -19 ± 10% versus -12 ± 11% (p<0.001). During a 2 year follow-up bleeding rates for PROP were 11% versus CARV 5% versus EBL 25% (p=0.0429). Fewer episodes of hepatic decompensation (PROP 38%/CARV 26% vs EBL 55%; p=0.0789) and significantly lower mortality (PROP 14%/CARV 11% vs EBL 31%; p=0.0455) were observed in haemodynamic responders compared to the EBL group.
Conclusions: Carvedilol leads to a significantly greater decrease in HVPG than propranolol. Using carvedilol for primary prophylaxis a substantial proportion of non-responders to propranolol can achieve a haemodynamic response, which is associated with improved outcome with regard to prevention of variceal bleeding, hepatic decompensation and death.
Keywords: Bleeding; Cirrhosis; Portal Hypertension.
Comment in
-
Carvedilol: the β-blocker of choice for portal hypertension?Gut. 2013 Nov;62(11):1529-30. doi: 10.1136/gutjnl-2012-304182. Epub 2013 Jan 26. Gut. 2013. PMID: 23355548 No abstract available.
Similar articles
-
Pharmacologic prevention of variceal bleeding and rebleeding.Hepatol Int. 2018 Feb;12(Suppl 1):68-80. doi: 10.1007/s12072-017-9833-y. Epub 2017 Dec 5. Hepatol Int. 2018. PMID: 29210030 Review.
-
Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.Gastroenterology. 2009 Jul;137(1):119-28. doi: 10.1053/j.gastro.2009.03.048. Epub 2009 Apr 1. Gastroenterology. 2009. PMID: 19344721 Clinical Trial.
-
Efficacy of carvedilol versus propranolol versus variceal band ligation for primary prevention of variceal bleeding.Hepatol Int. 2018 Jan;12(1):75-82. doi: 10.1007/s12072-017-9835-9. Epub 2017 Nov 28. Hepatol Int. 2018. PMID: 29185106 Clinical Trial.
-
Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.Hepatology. 1999 Jul;30(1):79-83. doi: 10.1002/hep.510300124. Hepatology. 1999. PMID: 10385642 Clinical Trial.
-
Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis.BMJ Open. 2016 May 4;6(5):e010902. doi: 10.1136/bmjopen-2015-010902. BMJ Open. 2016. PMID: 27147389 Free PMC article.
Cited by
-
Carvedilol versus propranolol in the prevention of variceal rebleeding in hepatosplenic schistosomiasis: Efficacy and safety.JGH Open. 2022 Mar 7;6(3):213-218. doi: 10.1002/jgh3.12721. eCollection 2022 Mar. JGH Open. 2022. PMID: 35355675 Free PMC article.
-
Elastography-based screening for esophageal varices in patients with advanced chronic liver disease.World J Gastroenterol. 2019 Jan 21;25(3):308-329. doi: 10.3748/wjg.v25.i3.308. World J Gastroenterol. 2019. PMID: 30686900 Free PMC article. Review.
-
Pharmacologic prevention of variceal bleeding and rebleeding.Hepatol Int. 2018 Feb;12(Suppl 1):68-80. doi: 10.1007/s12072-017-9833-y. Epub 2017 Dec 5. Hepatol Int. 2018. PMID: 29210030 Review.
-
β-Blockers in Hepatosplenic Schistosomiasis: A Narrative Review.Am J Trop Med Hyg. 2023 Nov 6;109(6):1213-1219. doi: 10.4269/ajtmh.23-0437. Print 2023 Dec 6. Am J Trop Med Hyg. 2023. PMID: 37931294 Free PMC article. Review.
-
Clinical Trial: A Multicentre Randomised Controlled Trial of Carvedilol Versus Variceal Band Ligation in Primary Prevention of Variceal Bleeding in Liver Cirrhosis (CALIBRE Trial).Aliment Pharmacol Ther. 2025 Jun;61(11):1740-1754. doi: 10.1111/apt.70080. Epub 2025 Apr 16. Aliment Pharmacol Ther. 2025. PMID: 40241373 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical